Correction: Efficacy and safety of fremanezumab in clinical trial participants aged ≥60 years with episodic or chronic migraine: pooled results from 3 randomized, double-blind, placebo-controlled phase 3 studies [0.03%]
关于偏头痛临床试验参与者（≥60岁）的疗效和安全性：来自3项随机、双盲、安慰剂对照的III期研究的汇总结果纠正通知
Stephanie J Nahas,Steffen Naegel,Joshua M Cohen et al.
Stephanie J Nahas et al.
Published Erratum
The journal of headache and pain. 2022 May 17;23(1):57. DOI:10.1186/s10194-022-01423-x 2022
Real-world effectiveness after initiating fremanezumab treatment in US patients with episodic and chronic migraine or difficult-to-treat migraine [0.03%]
在美国发作性、慢性 migraine 或难治性偏头痛患者中启动福马佐单抗治疗的现实效果
Maurice T Driessen,Joshua M Cohen,Stephen F Thompson et al.
Maurice T Driessen et al.
Background: Fremanezumab, a fully humanized monoclonal antibody (mAb; IgG2Δa) that selectively targets calcitonin gene-related peptide (CGRP), is approved for the preventive treatment of migraine in adults. The efficacy ...
Randomized Controlled Trial
The journal of headache and pain. 2022 May 16;23(1):56. DOI:10.1186/s10194-022-01415-x 2022
Twelve-month safety, tolerability and susceptibility to adverse events of prophylactic migraine therapy with erenumab: a retrospective real-world study [0.03%]
关于偏头痛预防性治疗药物欧乃派克安全性和耐受性的12个月回顾性真实世界研究：不良事件的易患性分析
Hannah Schenk,Dagny Holle,Michael Nsaka et al.
Hannah Schenk et al.
Background: Erenumab is a monoclonal antibody (mAb) against the calcitonin gene related peptide (CGRP) receptor and is commonly used in migraine prophylaxis. Pivotal and open-label studies show a good safety and tolerabil...
A real-world study of acute and preventive medication use, adherence, and persistence in patients prescribed fremanezumab in the United States [0.03%]
一项真实世界研究：美国启动福瑞曼珠单抗治疗患者的急性期与预防性药物使用、依从性和持续性
Lynda J Krasenbaum,Vasantha L Pedarla,Stephen F Thompson et al.
Lynda J Krasenbaum et al.
Background: Following approval of fremanezumab for the prevention of migraine in adults, health care decision makers are interested in understanding real-world clinical characteristics and treatment patterns among patient...
Calcitonin gene-related peptide-targeting drugs and Raynaud's phenomenon: a real-world potential safety signal from the WHO pharmacovigilance database [0.03%]
靶向降钙素基因相关肽的药物与雷诺现象：一项来自世界卫生组织药品不良反应数据库的真实世界潜在安全性信号研究
Alexandre O Gérard,Diane Merino,Elise K Van Obberghen et al.
Alexandre O Gérard et al.
Background: Migraine is responsible for significant disability and societal burden. Recently, drugs targeting the calcitonin gene-related peptide (CGRP) pathway raised new hopes. CGRP, a potent vasodilator, plays a key ro...
Central effects of galcanezumab in migraine: a pilot study on Steady State Visual Evoked Potentials and occipital hemodynamic response in migraine patients [0.03%]
一项关于Galcanezumab在偏头痛中中枢效应的试点研究：偏头痛患者的稳态视觉诱发电位和枕叶血流动力学反应
Marina de Tommaso,Marianna La Rocca,Silvia Giovanna Quitadamo et al.
Marina de Tommaso et al.
Background: The discovery of the prominent action of Calcitonin Gene Related Peptide -CGRP- on trigeminal afferents and meningeal vessels, opened a new era in migraine treatment. However, how the block of nociceptive affe...
Correction to: Fremanezumab in the prevention of high-frequency episodic and chronic migraine: a 12-week, multicenter, real-life, cohort study (the FRIEND study) [0.03%]
有关高频率发作性偏头痛和慢性偏头痛预防的fremanezumab疗效：FRIEND研究-多中心真实世界队列研究补遗
Piero Barbanti,Gabriella Egeo,Cinzia Aurilia et al.
Piero Barbanti et al.
Published Erratum
The journal of headache and pain. 2022 Apr 28;23(1):51. DOI:10.1186/s10194-022-01422-y 2022
Functionality, satisfaction, and global impression of change with ubrogepant for the acute treatment of migraine in triptan insufficient responders: a post hoc analysis of the ACHIEVE I and ACHIEVE II randomized trials [0.03%]
UBROGEPANT用于曲普坦疗效不足的急性偏头痛治疗的功能性、满意度和总体改善情况：来自ACHIEVE I 和II随机试验的事后分析
Richard B Lipton,Rashmi B Halker Singh,Dennis A Revicki et al.
Richard B Lipton et al.
Background: Triptans are the first-line option for the acute treatment of migraine attacks; however, triptans are contraindicated in people with certain underlying cardiovascular risk factors and are associated with inade...
The Global Campaign turns 18: a brief review of its activities and achievements [0.03%]
全球倡议项目十八岁了：简要回顾其活动与成就
Timothy J Steiner,Gretchen L Birbeck,Rigmor H Jensen et al.
Timothy J Steiner et al.
The Global Campaign against Headache, as a collaborative activity with the World Health Organization (WHO), was formally launched in Copenhagen in March 2004. In the month it turns 18, we review its activities and achievements, from initial...
Measuring dose-related efficacy of eptinezumab for migraine prevention: post hoc analysis of PROMISE-1 and PROMISE-2 [0.03%]
PROMISE-1和PROMISE-2的事后分析：eptinezumab预防性治疗偏头痛的剂量效应疗效评价
Rami Apelian,Lee Boyle,Joe Hirman et al.
Rami Apelian et al.
Background: Eptinezumab 100 mg and 300 mg met the primary efficacy endpoint in both PROMISE clinical trials, significantly reducing frequency of monthly migraine days over Weeks 1‒12. The objective of this analysis was t...